May 2002
641
9) Enzig A., Wiernik P. H., Sasloff J., Garl S., Runowicz C., O’Hanlon K.
A., Goldberg G., J. Clin. Oncol., 10, 1748—1753 (1992).
10) Rogers B. B., Oncol. Nurs. Forum, 20, 1483—1489 (1993).
11) Riondel J., Jacrot M., Fessi H., Puisieux F., Potier P., In Vivo, 6, 23—
27 (1992).
It is well established that large macromolecules circulating
for extended periods show substantial tumor accumulation.40)
In fact, CMDex molecules of 150 kDa or greater MW
demonstrate significantly higher accumulation in tumors than
in normal tissue with the exception of the spleen.27) The un- 12) Sharma A., Mayhew E., Straubinger R. M., Cancer Res., 53, 5877—
derlying physiological mechanism appears to be a combina-
tion of increased tumor vascular permeability with insuffi-
cient lymphatic drainage, resulting in what is termed the ‘en-
5881 (1993).
13) Sharma A., Straubinger R. M., Pharm. Res., 11, 889—895 (1994).
14) Straubinger R. M., Sharma A., Murray M., Mayhew E., J. Natl. Can-
cer Inst. Monogr., 15, 69—78 (1993).
hanced permeability and retention (EPR) effect’, thought to
be a universal solid tumor phenomenon for macromolecular
drugs.41)
15) Alkan-Onyuksel H., Ramakrishnan S., Chai H.-B., Pezzuto J. M.,
Pharm. Res., 11, 206—212 (1994).
16) Tarr B. D., Sambandan T. G., Yalkowsky S. H., Pharm. Res., 4, 162—
165 (1987).
It is quite possible that the use of different amino acids
within the CMDex-paclitaxel conjugate could affect the
amount and form of the paclitaxel reaching the tumor site.
Ideally, it would be desirable for release of the drug to occur
only in the vicinity of tumor cells, thereby sparing normal
cells from concomitant destruction. In the case of intact con-
jugate accumulation, there exist two possible pathways for
this conjugate’s breakdown in the tumor: simple ester hydrol-
ysis, or amide cleavage. The presence of functional peptidase
within the extracellular space of tumors42) certainly makes
the second pathway feasible. The production of amino acid
conjugated species has been implicated in the enhanced cel-
17) Wheeler J. J., Wong K. F., Ansell S. M., Masin D., Bally M. B., J.
Pharm. Sci., 83, 1558—1564 (1994).
18) Sharma D., Chelvi T. P., Kaur J., Chakravorty K., De T. K., Maitra A.,
Ralhan R., Oncol. Res., 8, 281—286 (1996).
19) Sharma U. S., Balasubramanian S. V., Straubinger R. M., J. Pharm.
Sci., 84, 1223—1230 (1995).
20) Greenwald R. B., Pendri A., Bolikal D., Gilbert C. W., Bioorg. Med.
Chem. Lett., 4, 2465—2470 (1994).
21) Li C., Yu D.-F., Newman R. A., Cabral F., Stephens L. C., Hunter N.,
Milas L., Wallace S., Cancer Res., 58, 2404—2409 (1998).
22) Chun L., Price J. E., Milas L., Hunter N. R., Shi K., Dong-Fang Y.,
Chusilp C., Wallace S., Clin. Cancer Res., 5, 891—897 (1999).
23) Monelli N., Angelucci F., Pesenti E., Suarato A., Biasoli G., US
Patent, 5,362,831 (1994).
lular uptake of daunorubicin.43) A recent paper has reported 24) Pesentie E., Franzetti C., Biasoli G., Ciomei M., Paston W., Marsiglio
A., Stegnjaich S., Mongelli N., Grandi M., Proc. Am. Assoc. Cancer
Res., 1995, 1824 (1995).
25) Greenwald R. B., Gilbert C. W., Pendri A., Conover C. D., Xia J., Mar-
on the cellular uptake of amino acid ester prodrugs by a pep-
tide transporter,44) making entrance into the cell theoretically
possible through either active or passive transport.
tinez A., J. Med. Chem., 39, 424—431 (1996).
Our current study has extended CMDex prodrug strategies
to include the use of spacer groups in paclitaxel modification
and was undertaken to determine the effect of various amino
acid spacers on the activity of CMDex-paclitaxel conjugates.
It was found that the use of specific amino acid spacers af-
fected the breakdown (dissociation) of CMDex-paclitaxel, its
in vivo efficacy, and its toxicity. Conjugating 150 kDa of
CMDex to 2Ј-gly paclitaxel results in a homogeneous water-
soluble prodrug with less toxicity and enhanced anti-tumor
activity compared with the resultant native drug. Work is
now expanding on the effect of substituting other linkage for
gly in the CMDex-paclitaxel delivery system, as well as ex-
amining different CMDex-spacer-paclitaxel transport forms
in a variety of in vivo applications.
26) Vasey P. A., Duncan R., Kaye S. B., Cassidy F., Eur. J. Cancer, 31A,
S193 (1995).
27) Sugahara S., Okuno S., Yano T., Hamana H., Inoue K., Biol. Pharm.
Bull., 24, 535—543 (2001).
28) Daotian F., Roger A. O., Anal. Biochem., 227, 377—384 (1995).
29) Honda S., Akao E., Suzuki S., Okuda M., Kakei K., Nakamura J.,
Anal. Biochem., 180, 351—357 (1989).
30) Larm O., Lindberg B., Svensson S., Carbohyd. Res., 20, 39—48
(1971).
31) Mase H., Hiraoka M., Suzuki A., Nakanomyo H., Yakugaku Zasshi,
114, 351—355 (1994).
32) Mathew A. E., Mejillano M. R., Nath J. P., Himes R. H., Stella V. J., J.
Med. Chem., 35, 145—151 (1992).
33) Ringel I., Horwitz S. B., J. Pharmacol. Exp. Ther., 242, 692—698
(1987).
34) Takakura Y., Hashida M., Crit. Rev. Oncol. Hematol., 18, 207—231
(1995).
35) Deutsch H. M, Glinski J. A, Hernandez M., Haugwitz R. D., Narayan
V. L., Suffness M., Zalkow L. H., J. Med. Chem., 32, 788—792
(1989).
REFERENCES
36) Zhao Z., Kingston D. G. I., Crosswell A. R., J. Natur. Prod., 54,
1607—1611 (1991).
1) Wani M. C., Taylor H. L., Wall M. E., Coggon P., McPhail A. T., J.
Am. Chem. Soc., 93, 2325—2327 (1971).
37) Hansch C., Leo A., “Exploring QSAR,” ed. by Heller S. R., ACS Pro-
fessional Reference Book, American Chemical Society, 1995, pp.
69—96.
38) Soyez H., Schacht E., Vanderkerken S., Adv. Drug Deliv. Rev., 21,
81—106 (1996).
39) Mathew A. E., Mejillano M. R., Nath J. P., Himes R. H., Stella V. J., J.
Med. Chem., 35, 145—151 (1992).
40) Maeda H., Seymour L., Miyamoto Y., Bioconjugate Chem., 3, 351—
362 (1992).
41) Maeda H., Adv. Drug Deliv. Rev, 6, 181—202 (1991).
42) Hess R., Cancer Res., 20, 940—943 (1960).
43) Baurain R., Masquelier M., Deprez-De C. D., Trouet A., J. Med.
Chem., 23, 1171—1174 (1980).
2) Long H. J., Mayo Clin. Proc., 69, 341—345 (1994).
3) Cahan M. A., Walter K. A., Colvin O. M., Brem H., Cancer
Chemother. Pharmacol., 33, 441—444 (1994).
4) Wiernik P. H., Einzig A. I., Monogr. Natl. Cancer Inst., 15, 185—187
(1993).
5) Arbuck S. G., Christian M. C., Fisherman J. S., Cazenave L. A.,
Sarosy G., Suffness M., Adams J., Canetta R., Cole K. E., Friedman
M. A., Monogr. Natl. Cancer Inst., 15, 11—24 (1993).
6) Foa R., Norton L., Seidman A. D., Int. J. Clin. Lab. Res., 24, 6—14
(1994).
7) Lopes N. M., Adams E. G., Pitts T. W., Bhuyan B. K., Cancer
Chemother. Phrmacol., 32, 235—242 (1993).
8) Weiss R. B., Donehower R. V., Wiernik P. H., Ohnuma T., Gralla R. J.,
Trump D. L., Baker J. R., Van Echo D. A., VonHoff D. D., Leyland
Jones B., J. Clin. Oncol., 8, 1263—1268 (1990).
44) Han H., Oh D., Amidon G. L., Pharm. Res., 15, 1382—1386 (1998).